Clinical trials: Advanced Rectal Cancers
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
This study is to evaluate the safety and tolerability of of LT-010391 as monotherapy in participants with KRAS G12D mutant advanced solid tumors
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT07624214
- Testing
- LT-010391
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Advanced Solid Tumors, Triple Negative Breast Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03797326
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 88 sites in United States, Argentina and 15 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Neoplasms, Metastatic Cancer
A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors
Evaluate the safety and tolerability of BPI-421286 in adult subjects with advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with advanced solid tumors.
- Trial name
- NCT05315180
- Testing
- BPI-421286
- Where
- 5 sites in China
- Volunteers
- 80 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Advanced Solid Tumor, Non-Small Cell Lung Cancer
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or…
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07629960
- Testing
- BLU-924
- Where
- 16 sites in United States, Spain
- Volunteers
- 265 people
- Sponsor
- Blueprint Medicines Corporation
Colorectal Neoplasms, Neoplasms
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
This study determined the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with FOLFOX [Leucovorin + Fluorouracil (5-FU) + Oxaliplatin].
- Trial name
- NCT00599924
- Testing
- sunitinib + FOLFOX
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pfizer
Colorectal Carcinoma
Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal Carcinoma With AMT2003
The purpose of the study is to evaluate efficacy and safety of AMT2003 in cancer patients with advanced colorectal carcinoma. The primary endpoint is progression free survival rate at 18 weeks after registration
- Trial name
- NCT00405561
- Testing
- AMT2003
- Where
- Germany
- Volunteers
- 67 people
- Sponsor
- Auron Healthcare GmbH
Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC)
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
The main aim of this study is to check for side effects and tolerability of TAK-186 (also known as MVC-101) in adults with unremovable advanced or metastatic cancer.
- Conditions
- Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
- Trial name
- NCT04844073
- Testing
- TAK-186
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 95 people
- Sponsor
- Takeda
Breast Cancer, Head and Neck Squamous Cell Carcinoma
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Many patients have cancers that have increased activity of a protein called STAT3 that contributes critically to the development and growth of their cancer.
- Conditions
- Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer
- Trial name
- NCT03195699
- Testing
- TTI-101
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Tvardi Therapeutics, Incorporated
Colorectal Cancer, Gastric Cancer
Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
This is an open-label, multi-center, dose escalation study in adult subjects with advanced colorectal, gastric, hepatic or pancreatic cancer.
- Conditions
- Colorectal Cancer, Gastric Cancer, Hepatic Cancer, Pancreatic Cancer
- Trial name
- NCT02191761
- Testing
- SM04755
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Biosplice Therapeutics, Inc.
Breast Cancer, Cholangiocarcinoma
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion.
- Conditions
- Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
- Trial name
- STARTRK-2 (NCT02568267)
- Testing
- Entrectinib
- Where
- 120 sites in United States, Australia and 14 more
- Volunteers
- 534 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors, Cancer
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for…
- Conditions
- Advanced Solid Tumors, Cancer, Hematologic Malignancies
- Trial name
- NCT03082209
- Testing
- ABBV-621, Venetoclax, Bevacizumab
- Where
- 19 sites in United States, Japan and 2 more
- Volunteers
- 153 people
- Sponsor
- AbbVie
Triple-negative Breast Cancer, NSCLC, Squamous or Non-Squamous
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
This is an open-label, multicenter, phase Ib study to evaluate the safety and preliminary efficacy of AN0025 in combination with pembrolizumab in patients with locally advanced/metastatic tumors.
- Conditions
- Triple-negative Breast Cancer, NSCLC, Squamous or Non-Squamous, Urothelial Carcinoma of the Bladder, Microsatellite Stable (MSS) Colorectal Cancer (CRC)
- Trial name
- NCT04432857
- Testing
- AN0025, Pembrolizumab
- Where
- 6 sites in United States, France
- Volunteers
- 63 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck
Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
This is a Phase I multicenter, open label, nonrandomized study of enadenotucirev administered in combination with nivolumab in subjects with metastatic or advanced epithelial tumors (with focus on CRC, SCCHN, escalation phase)…
- Conditions
- Colorectal Cancer, Squamous Cell Carcinoma of the Head and Neck, Epithelial Tumor
- Trial name
- SPICE (NCT02636036)
- Testing
- enadenotucirev, nivolumab
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Akamis Bio
Advanced Solid Tumors
A Study of ASP1951 in Subjects With Advanced Solid Tumors
The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or…
- Trial name
- NCT03799003
- Testing
- ASP1951, pembrolizumab
- Where
- 32 sites in United States, Canada and 2 more
- Volunteers
- 119 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Solid Tumor
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies.
- Trial name
- NCT01607905
- Testing
- Selinexor, Acetaminophen
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 192 people
- Sponsor
- Karyopharm Therapeutics Inc
Solid Malignancies, Non-Hodgkin's Lymphoma
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
The purposes of this study are to determine: the largest dose of AQ4N that can be safely given once a week for three weeks out of a 4 week cycle the side effects of AQ4N when given on the above schedule how much AQ4N is in the…
- Trial name
- NCT00090727
- Testing
- AQ4N
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novacea
Imaging, Colorectal Cancer
A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.
LNTH-2403 (177Lu-DOTA-DUNP19) is a lutetium-177 radiolabeled, fully humanized monoclonal antibody (mAb) that binds with high specificity and affinity to leucine-rich repeat containing 15 (LRRC15), a transforming growth factor…
- Conditions
- Imaging, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer
- Trial name
- DUNP19 (NCT07272642)
- Testing
- LNTH-2403
- Where
- Australia
- Volunteers
- 16 people
- Sponsor
- Radiopharm Theranostics, Ltd
Cancer, Colon Cancer
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
This is a phase 3, randomized, double-blind, placebo-controlled multi-center study evaluating the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia (FN) in patients with newly diagnosed, locally-advanced or…
- Conditions
- Cancer, Colon Cancer, Colorectal Cancer, Fever
- Trial name
- NCT00911170
- Testing
- Pegfilgrastim, Bevacizumab, Standard Chemotherapy
- Where
- 154 sites in United States, Australia and 15 more
- Volunteers
- 847 people
- Sponsor
- Amgen
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company